Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.
LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m. ET, and management will host one-on-one meetings with investors.
A live webcast of the fireside chat will be available on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the conclusion of the event.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529163130/en/
Contacts
Investor Contact:
Nick Smith
investors@altoneuroscience.com
Media Contact:
Jordann Merkert
media@altoneuroscience.com
Source: Alto Neuroscience, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240529163130/en
